Single-agent dual-action cancer treatments
The company is developing treatments intended to inhibit both cancer growth and immunosuppression.
Source: LinkedIn company description · Retrieved October 13, 2026
Trio Pharmaceuticals is a cancer therapeutics company focused on improving cancer drug efficacy, reducing toxicity, and increasing treatment affordability.
The company describes its team as experienced in cancer drug discovery and development.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company’s approach is intended for cancer patients whose immune checkpoint treatments failed because of resistance or low expression of PD1, PDL1, CTLA4, or related targets.
The company is developing treatments intended to inhibit both cancer growth and immunosuppression.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 27, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026, September 21, 2026, September 27, 2026, September 28, 2026, September 30, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.